A Study of ASN007 in Patients With Advanced Solid Tumors

• ClinicalTrials.gov Identifier: NCT03415126
• Recruitment Status: Completed
• First Posted: January 30, 2018
• Last Update Posted: July 9, 2020
• Sponsor: Asana BioSciences
• Information provided by (Responsible Party): Asana BioSciences

Tracking Information

• First Submitted Date: January 15, 2018
• First Posted Date: January 30, 2018
• Last Update Posted Date: July 9, 2020
• Actual Study Start Date: January 19, 2018
• Actual Primary Completion Date: June 30, 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 29, 2018)

• Part A: Determine the maximum tolerated dose (MTD) of ASN007 [ Time Frame: First 21 days ]
  The MTD will be determined by evaluating the number of subjects with treatment related dose limiting toxicity. This is the primary endpoint of Part A
• Part B: evaluate the overall response rate (number of Complete Responses + Partial Responses) in subjects receiving ASN007 for the treatment of metastatic melanoma, CRC, NSCLC, or pancreatic cancer. [ Time Frame: First 6 months ]
  This is the primary endpoint for Part B.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: May 18, 2018)

• Calculate the pharmacokinetic area under the plasma concentration (AUC) of ASN007 [ Time Frame: First 21 days ]
  Calculate the amount of ASN007 in the bloodstream
• Calculate the maximum plasma concentration (Cmax) at steady state. [ Time Frame: First 21 days ]
  Calculate the maximum amount of ASN007 in the bloodstream
• Calculate the terminal elimination rate (T 1/2). [ Time Frame: First 21 days ]
  Calculate how fast ASN007 leaves the body

Original Secondary Outcome Measures (submitted: January 29, 2018)

• Calculate the pharmacokinetic area under the plasma concentration (AUC) of ASN007 [ Time Frame: First 21 days ]
  Calculate the amount of ASN007 in the bloodstream
• Calculate the maximum plasma concentration (Cmax) at steady state. [ Time Frame: First 21 days ]
  Calculate the maximum amount of ASN007 in the bloodstream
• Calculate the terminal elimination rate (T 1/2). [ Time Frame: First 21 days ]
  Calculate how fast ASN002 leaves the body

Current Other Pre-specified Outcome Measures (submitted: February 12, 2019)

• To evaluate the change from baseline in the intensity of phosphorylated ribosomal S6 kinase (RSK) found in tumor biopsies. [ Time Frame: Through the study, average 6 months ]
  Evaluate the effect of ASN007 on biomarkers
• Evaluate the change from baseline in the amount of circulating tumor DNA [ Time Frame: Every 8 weeks for the first 24 weeks, then every 12 weeks for up to 1 year ]
  Evaluate the effect of ASN007 on biomarkers

Original Other Pre-specified Outcome Measures (submitted: January 29, 2018)

• To evaluate the change from baseline in the intensity of phosphorylated ribosomal S6 kinase (RSK) found in tumor biopsies. [ Time Frame: Through the study, average 6 months ]
  Evaluate the effect of ASN007 on biomarkers
• To evaluate the change from baseline in the intensity of Ribosomal S6 Kinase (RSK) found in circulating tumor cells. [ Time Frame: Through the study, average 6 months ]
  Evaluate the effect of ASN007 on biomarkers
• Evaluate the change from baseline in the amount of circulating tumor DNA [ Time Frame: Every 8 weeks for the first 24 weeks, then every 12 weeks for up to 1 year ]
  Evaluate the effect of ASN007 on biomarkers

Descriptive Information

• Brief Title: A Study of ASN007 in Patients With Advanced Solid Tumors
• Official Title: A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
• Brief Summary: The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

Detailed Description

Part A is a dose escalation study to determine a safe and tolerable dose of ASN007 for patients with advanced solid tumors. Part A will also describe how the body works on ASN007(pharmacokinetics) and the effects of ASN007 on the body (pharmacodynamics) of ASN007, through blood sampling and optional biopsies..

Part B of the study will enroll patients with particular tumor types and genetic mutations for treatment at the Recommended Phase 2 Dose. Part B will enroll patients in five groups of fifteen patients each:

Group 1: Patients with metastatic BRAF mutated melanoma Group 2: Patients with metastatic NRAS and HRAS mutated solid tumors Group 3: Patients with metastatic KRAS mutated colorectal cancer (CRC) Group 4: Patients with metastatic KRAS mutated non-small cell lung cancer (NSCLC) Group 5: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Patients with melanoma will be required to have pre-dose and post-dose biopsies.

Group 6: Patients with metastatic MEK1, BRAF V600E, non-BRAF V600E solid tumors or BRAF fusions without prior treatment with BRAF, MEK, ERK inhibitors

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Cancer
• Malignancy
• Neoplasia
• Neoplasm
• Neoplasm Metastasis
• Colon Cancer
• Colonic Neoplasms
• Colon Cancer Liver Metastasis
• Metastatic Cancer
• Metastatic Melanoma
• Metastatic Colon Cancer
• Metastatic Lung Cancer
• Non Small Cell Lung Cancer Metastatic
• Pancreatic Cancer
• Pancreas Cancer
• Pancreas Adenocarcinoma
• Pancreas Neoplasm
• Metastatic Nonsmall Cell Lung Cancer
• Metastatic Pancreatic Cancer

Intervention

• Drug: ASN007: ascending doses
  Oral drug for the treatment of advanced solid tumors
• Drug: ASN007 RD
  Oral drug for the treatment of advanced solid tumors

Study Arms

• Experimental: ASN007 ascending doses
  Patients will receive escalating doses of ASN007 to identify the best dose.
  Intervention: Drug: ASN007: ascending doses
• Experimental: ASN007 RD: KRAS mutant Melanoma
  Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
  Intervention: Drug: ASN007 RD
• Experimental: ASN007 RD: NRAS mutant Melanoma
  Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
  Intervention: Drug: ASN007 RD
• Experimental: ASN007 RD: KRAS mutant metastatic CRC
  Patients with KRAS mutant CRC will receive the recommended dose from Part A
  Intervention: Drug: ASN007 RD
• Experimental: ASN007 RD: KRAS mutant NSCLC
  Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
  Intervention: Drug: ASN007 RD
• Experimental: ASN007 RD: Metastatic Pancreatic Cancer
  Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
  Intervention: Drug: ASN007 RD
• Experimental: ASN007 RD: MEK, All BRAF, BRAF-fusion cancers
  Patients with solid tumors will receive the recommended dose from Part A
  Intervention: Drug: ASN007 RD

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 6, 2019): 49
• Original Estimated Enrollment (submitted: January 29, 2018): 110
• Actual Study Completion Date: June 30, 2020
• Actual Primary Completion Date: June 30, 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Written informed consent obtained prior to any study-related procedure being performed;
• Male or non-pregnant, non-lactating female patient at least 18 years of age at the time of consent;
• Eastern Cooperative Oncology Group Performance Status 0-1 (Part A) and PS 0-2 (Part B)
• Histologically or cytologically confirmed
• advanced or metastatic solid tumor (Part A)
• Group 1: BRAF mutant melanoma (Part B)
• Group 2: NRAS or HRAS mutant solid tumors(Part B)
• Group 3: KRAS mutant CRC.(Part B)
• Group 4: KRAS mutant NSCLC (Part B)
• Group 5: Pancreatic Ductal Adenocarcinoma (Part B)
• Progressive disease after failure of or intolerant to all available standard systemic treatments that have shown a documented benefit in overall survival for their respective tumor type.
• Measurable or evaluable disease per RECIST v1.1
• Screening hematology values of the following:
• absolute neutrophil count ≥ 1000/μL,
• platelets ≥ 100,000/μL,
• hemoglobin ≥ 9 g/dL
• Screening chemistry values of the following:
• alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3.0 × upper limit of the normal (ULN),
• total bilirubin ≤ 1.5 × ULN,
• creatinine ≤ 1.5 × ULN,,
• albumin ≥ 2.8 g/dL.
• Screening heart function lab test
• creatinine kinase - MB, troponin-I, and troponin-T within normal limits
• Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned.

Exclusion Criteria:

• Prior treatment with ASN007 or another ERK1/2 inhibitor
• Known hypersensitivity to ASN007 or its excipients;
• Part B: Prior treatment with a RAF or MEK pathway inhibitor, except BRAFmutant melanoma (Group 1)
• Prior chemotherapy, targeted therapy or monoclonal antibody therapy within 3 weeks of start of study treatment (Day1), or 5 half-lives, whichever is shorter.
• Concurrent or prior bone marrow factors (e.g. G-CSF, GM-CSF or erythropoietin) within 3 weeks prior to Day 1 of treatment.
• Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatment
• Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.
• History of or current evidence / risk of retinal vein occlusion (RVO) central serous retinopathy (CSR), or glaucoma with intraocular pressures ≥ 21 mmHg or other pre-existing ocular conditions that may put the patient at risk for ocular toxicities
• Known central nervous system (CNS) primary tumor, CNS metastases or carcinomatous meningitis (Part A). Patients may be enrolled with CNS metastasis in certain circumstances in Part B.
• Clinically significant heart disorders including an ejection fraction of < 50%
• Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,
• Any other condition that might place the patient at undue risk.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03415126
• Other Study ID Numbers: ASN007-101
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Asana BioSciences
• Original Responsible Party: Same as current
• Current Study Sponsor: Asana BioSciences
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Medical Monitor; Asana BioSciences

• PRS Account: Asana BioSciences
• Verification Date: July 2020